Equity Details
Price & Market Data
Price: $1.42
Daily Change: +$0.0299 / 2.11%
Daily Range: $1.39 - $1.44
Market Cap: $898,129,344
Daily Volume: 26,741,812
Performance Metrics
1 Week: -15.15%
1 Month: -19.08%
3 Months: -13.58%
6 Months: 30.84%
1 Year: 9.38%
YTD: 6.06%
About Geron Corporation (GERN)
Dive into the latest financial snapshot of Geron Corporation (GERN). With a current trading price of 1.42, the stock has experienced a daily shift of +$0.0299 / 2.11%. The company's market capitalization stands impressively at 898,129,344. Track its year-to-date performance, which is at 6.06%, alongside its weekly, monthly, and yearly trends.
Company Details
Employees: 258
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.